Scholarlink

<p>Hereditary gelsolin amyloidosis (AGel) is a rare and often underrecognized protein misfolding disorder caused by mutations in the gelsolin (GSN) protein, leading to its aggregation in various tissues. Its rarity, combined with a heterogeneous and complex clinical presentation and the multidomain, flexible nature of GSN, has impeded research into its pathogenic mechanisms and therapeutic options. GSN comprises six homologous domains, labeled sequentially from G1 to G6. For over 40&#xa0;years, AGel amyloidosis was exclusively linked to a systemic form, caused by D187N and D187Y mutations in the second domain, referred to as the Finnish and Danish variants. However, since 2013, numerous novel amyloidogenic variants have been identified in different protein regions, leading to various clinical phenotypes, characterized by distinct molecular mechanisms. This review examines these mutations and proposes a classification based on molecular and clinical features to enhance research and diagnosis. Additionally, we summarize whether elucidating the different pathogenic mechanisms aids in identifying potential druggable targets. The lack of information and biological models and limited efforts to develop pharmacological treatments highlight the need for further therapeutic exploration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A molecular perspective of gelsolin amyloidosis: An old foe with new faces

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月15日

查看全文
  • Michela Bollati,
  • Carmina Natale,
  • Loic Girois,
  • Andrea Conz,
  • Kaliroi Peqini,
  • Stefano Pieraccini,
  • Sara Pellegrino,
  • Luisa Diomede,
  • Matteo de Rosa

摘要

Hereditary gelsolin amyloidosis (AGel) is a rare and often underrecognized protein misfolding disorder caused by mutations in the gelsolin (GSN) protein, leading to its aggregation in various tissues. Its rarity, combined with a heterogeneous and complex clinical presentation and the multidomain, flexible nature of GSN, has impeded research into its pathogenic mechanisms and therapeutic options. GSN comprises six homologous domains, labeled sequentially from G1 to G6. For over 40 years, AGel amyloidosis was exclusively linked to a systemic form, caused by D187N and D187Y mutations in the second domain, referred to as the Finnish and Danish variants. However, since 2013, numerous novel amyloidogenic variants have been identified in different protein regions, leading to various clinical phenotypes, characterized by distinct molecular mechanisms. This review examines these mutations and proposes a classification based on molecular and clinical features to enhance research and diagnosis. Additionally, we summarize whether elucidating the different pathogenic mechanisms aids in identifying potential druggable targets. The lack of information and biological models and limited efforts to develop pharmacological treatments highlight the need for further therapeutic exploration.